Biofilm response and removal via the coupling of visible-light-driven photocatalysis and biodegradation in an environment of sulfamethoxazole and Cr(Ⅵ)

The widespread contamination of water systems with antibiotics and heavy metals has gained much attention.Intimately coupled visible-light-responsive photocatalysis and biodegradation(ICPB)provides a novel approach for removing such mixed pollutants.In ICPB,the photocatalysis products are biodegraded by a protected biofilm,leading to the mineralization of refractory organics.In the present study,the ICPB approach exhibited excellent photocatalytic activity and biodegradation,providing up to~1.27 times the degradation rate of sulfamethoxazole(SMX)and 1.16 times the Cr(Ⅵ)reduction rate of visiblelight-induced photocatalysis.Three-dimensional fluorescence analysis demonstrated the synergistic ICPB effects of photocatalysis and biodegradation for removing SMX and reducing Cr(Ⅵ).In addition,the toxicity of the SMX intermediates and Cr(Ⅵ)in the ICPB process significantly decreased.The use of MoS_(2)/CoS_(2)photocatalyst accelerated the separation of electrons and holes,with·O_(2)^(–)and h+attacking SMX and ereducing Cr(Ⅵ),providing an effective means for enhancing the removal and mineralization of these mixed pollutants via the ICPB technique.The microbial community results demonstrate that bacteria that are conducive to pollutant removal are were enriched by the acclimation and ICPB operation processes,thus significantly improving the performance of the ICPB system.

A novel silicone derivative of natural osalmid(DCZ0858)induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway

Diffuse large B-cell lymphoma(DLBCL)is a highly heterogeneous malignant tumor characterized by diffuse growth.DCZ0858 is a novel small molecule with excellent antitumor effects in DLBCL.This study explored in depth the inhibitory effect of DCZ0858 on DLBCL cell lines.Cell Counting Kit-8(CCK-8)and plate colony formation assays were used to evaluate cell proliferation levels.Flow cytometry was employed to analyze apoptosis and the cell cycle,and western blotting was used to quantify the expression of cell cycle regulators.The results indicated that DCZ0858 inhibited cell growth in a concentration-dependent and time-dependent manner while inducing no significant toxicity in normal cells.Moreover,DCZ0858 initiated cell apoptosis via both internal and external apoptotic pathways.DCZ0858 also induced cell cycle arrest in the G0/G1 phase,thereby controlling cell proliferation.Further investigation of the molecular mechanism showed that the JAK2/STAT3 pathway was involved in the DCZ0858-mediated antitumor effects and that JAK2 was the key target for DCZ0858 treatment.Knockdown of JAK2 partly weakened the DCZ0858-mediated antitumor effect in DLBCL cells,while JAK2 overexpression strengthened the effect of DCZ0858 in DLBCL cells.Moreover,a similar antitumor effect was observed for DCZ0858 and the JAK2 inhibitor ruxolitinib,and combining the two could significantly enhance cancer-suppressive signaling.Tumor xenograft models showed that DCZ0858 inhibited tumor growth in vivo and had low toxicity in important organs,findings that were consistent with the in vitro data.In summary,DCZ0858 is a promising drug for the treatment of DLBCL.